Furthermore, there have been multiple inhibitors developed against FASN, for example, cerulenin, which increases survival rates and improves anti-tumour immune response in xenograft ovarian models, and orlistat—a drug which demonstrates synergy with cisplatin in vivo. The gene discussed is FASN; the disease is neoplasm.